First patient dosed in phase 2 trial for SURF-200 for acute dry eye
The first patient has been dosed in the phase 2 clinical trial for SURF-200 (betamethasone in Klarity vehicle; Surface Ophthalmics, Inc) for the treatment of acute dry eye, according to a press release.
Between 120-140 patients will be enrolled in the trial studying SURF-200 in 2 different low concentration formulations which include betamethasone. The primary endpoint is symptom improvement of 1 unit based on the University of North Carolina Dry Eye Management Scale by day 8.
“With limited treatment options for acute dry eye, we have a great need for an effective and well-tolerated therapeutic for patients suffering from periodsof acute dry eye,” stated Preeya Gupta, MD, Associate Professor of Ophthalmology at Duke University Eye Center, lead investigator for the SURF-200 clinical trial, in a press release. “With a proven diluent designed to protect the ocular surface and a potent corticosteroid, I’m hopeful that SURF-200 will provide a much-needed treatment option.”
Read the full press release here.
